Celgene Corp. Hits New 52-Week High at $158.44 (CELG)
Shares of Celgene Corp. (NASDAQ:CELG) hit a new 52-week high during trading on Wednesday, StockRatingsNetwork.com reports. The stock traded as high as $158.44 and last traded at $157.38, with a volume of 1,952,674 shares trading hands. The stock had previously closed at $155.25.
A number of analysts have recently weighed in on CELG shares. Analysts at RBC Capital raised their price target on shares of Celgene Corp. from $150.00 to $170.00 in a research note to investors on Wednesday, October 9th. They now have an “outperform” rating on the stock. Separately, analysts at Bank of America Corp. raised their price target on shares of Celgene Corp. from $164.00 to $179.00 in a research note to investors on Tuesday, October 8th. They now have a “buy” rating on the stock. Finally, analysts at TheStreet reiterated a “buy” rating on shares of Celgene Corp. in a research note to investors on Monday, October 7th. Five research analysts have rated the stock with a hold rating and twenty-three have assigned a buy rating to the company’s stock. Celgene Corp. currently has an average rating of “Buy” and an average target price of $145.15.
Celgene Corp. has a 52-week low of $71.23 and a 52-week high of $157.95. The stock has a 50-day moving average of $148.9 and a 200-day moving average of $132.0. The company has a market cap of $65.117 billion and a P/E ratio of 43.41.
Celgene Corp. (NASDAQ:CELG) last released its earnings data on Thursday, July 25th. The company reported $1.52 earnings per share for the quarter, beating the analysts’ consensus estimate of $1.44 by $0.08. The company had revenue of $1.56 billion for the quarter, compared to the consensus estimate of $1.54 billion. During the same quarter last year, the company posted $1.22 earnings per share. Celgene Corp.’s revenue was up 17.0% compared to the same quarter last year. On average, analysts predict that Celgene Corp. will post $5.98 earnings per share for the current fiscal year.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.